MedWatch

Lundbeck and Teva settle compensation case for millions

Teva and Lundbeck have settled a year-long legal dispute about DKK 114 million (USD 18.79 million) out of court.

Foto: /ritzau/Jens Dresling

After nearly nine years, Lundbeck and the Teva-owned generics company Actavis seem to finally have settled a legal dispute.

Actavis, acquired by Israeli Teva in 2016, initially demanded DKK 114 million (USD 18.79 million) from Lundbeck as compensation for unlawfully keeping the company’s generic versions of a Lundbeck drug away from the Danish market. 

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier